Converging data from epidemiological and biological research implicate insulin-like growth factor (IGF) physiology in the regulation of prostate epithelial cell proliferation and in the pathophysiology of prostate cancer. This review (1) outlines elements of IGF physiology, (2) reviews recent evidence that circulating IGF-I level is related to risk of prostate cancer, (3) provides a hypothesis concerning the biological basis for the relationship between IGF-I level and risk of prostate cancer, (4) discusses IGF-I physiology in the context of neoplastic progression of prostate cancer, and (5) discusses clinical implications of these lines of research with respect to prevention and treatment.

Animals↗

PubMedDate not supplied

[Differential diffusion of AIDS. A sociologic approach].

Explore the source record for details and available documents.

Acquired Immunodeficiency Syndrome↗

PubMedDate not supplied

Sodium nitroprusside pharmacoangiography: arteriographic enhancement by local vasodilation.

Sodium nitroprusside (SNP) was injected intra-arterially into the right femoral artery of five dogs, to promote arteriographic enhancement with minimal systemic effects. Injection of 3 microgram/Kg SNP or more, produced tachycardia, hypotension and increased pulsatile arterial blood flow. a 36% pulsatile arterial flow increase, which lasted 25 seconds or less, was the most remarkable systemic change seen after intra-arterial injection of 2.5 microgram/Kg SNP. Small doses were followed by even lesser systemic changes but were ineffective in promoting arteriographic enhancement. Comparison of arteriograms obtained before and after 2.5 microgram/Kg SNP injection showed increased arterial diameter, greater architectural detail and extensive visualization of previously undetected smaller arteries in post-SNP angiograms. Thus, suggesting that 2.5 microgram/Kg was the optimal SNP dose for production of local arterial without remarkable systemic effects. Good results of SNP pharmacoangiography in this experimental series suggest that further research on this topic is warranted.

Angiography↗

PubMedDate not supplied

The potential role of somatostatin analogues in breast cancer treatment.

Existing treatments for breast cancer are helpful for many patients, but treatment failure remains a common event, and there is a strong clinical need to improve upon current therapies. Somatostatin analogues have been evaluated for antineoplastic activity in model systems over the past decade, and encouraging results have been obtained (reviewed in [1, 2]). This has led to suggestions to test these agents clinically in the treatment of breast cancer patients, and a program of clinical trials has recently been initiated. This review will describe aspects of research in this area.

Antineoplastic Agents, Hormonal↗